Psychedelics
Psychedelic Sector News – Weekly Extractions: September 23, 2022
In this edition of Weekly Extractions, host Adam Tubero provides an update on a story we’ve been following closely over the past several weeks. For starters,…
In this edition of Weekly Extractions, host Adam Tubero provides an update on a story we’ve been following closely over the past several weeks.
For starters, MindMed’s stock has been quite volatile of late.
It all started last week with the Weekly Extractions edition from August 13th where Adam calls out a letter written to the MindMed team from Scott Freeman.
Next, Adam interviewed Scott Freeman. The video interview spanned two parts. Check out part 1 and part 2.
MindMed popped up once again on August 24th in a unique story that tied their stock to Bed Bath and Beyond.
MindMed was once again highlighted on August 27th and again in a dedicated Weekly Extractions on September 6th.
As if that wasn’t enough, the September 12th episode dove into MindMed once more.
On top of all of that, they’ve been in the press quite a bit across our website along the way:
- August 25th: MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
- September 8th: MindMed Announces Positive Results from Collaborators’ Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
- September 14th: MindMed Announces Compliance with Nasdaq Listing Requirements
- September 20th: MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
We hope you enjoy today’s Weekly Extractions – once again, dedicated to more news surrounding MindMed.
For more information on MindMed ($MNMD), check out their company profile on Psychedelic Invest.
Please like, share, comment, and subscribe on YouTube. There will be plenty more Weekly Extractions in the weeks to come.
Psychedelic Search Trends in 2023
Take a look at this 2023 search volume chart. Do you think you can guess what’s happening? I was pretty shocked when I noticed this spike for December…
Here Are the Champions! Our Top Performing Stories in 2023
It has been quite a year – not just for the psychedelic industry, but also for humanity as a whole. Volatile might not be the most elegant word for it,…
Psilocybin shows promise for treating eating disorders, but more controlled research is needed
Recent psychedelic research shows promising results for mental illnesses and eating disorders, with surveys and reports indicating psilocybin-assisted…
